ADMA Biologics (NASDAQ:ADMA) and Windtree Therapeutics (NASDAQ:WINT) are both small-cap medical companies, but which is the better business? We will compare the two businesses based on the strength of their earnings, dividends, valuation, institutional ownership, profitability, risk and analyst recommendations.
Insider and Institutional Ownership
48.9% of ADMA Biologics shares are owned by institutional investors. Comparatively, 1.6% of Windtree Therapeutics shares are owned by institutional investors. 11.7% of ADMA Biologics shares are owned by company insiders. Comparatively, 14.9% of Windtree Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company will outperform the market over the long term.
Analyst Ratings
This is a summary of recent recommendations and price targets for ADMA Biologics and Windtree Therapeutics, as reported by MarketBeat.com.
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score |
|---|
| ADMA Biologics | 0 | 0 | 5 | 0 | 3.00 |
| Windtree Therapeutics | 0 | 0 | 1 | 0 | 3.00 |
ADMA Biologics presently has a consensus target price of $7.80, suggesting a potential upside of 372.73%. Windtree Therapeutics has a consensus target price of $12.25, suggesting a potential upside of 472.43%. Given Windtree Therapeutics' higher probable upside, analysts plainly believe Windtree Therapeutics is more favorable than ADMA Biologics.
Profitability
This table compares ADMA Biologics and Windtree Therapeutics' net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets |
|---|
| ADMA Biologics | -166.01% | -98.83% | -37.21% |
| Windtree Therapeutics | N/A | -43.46% | -26.55% |
Valuation and Earnings
This table compares ADMA Biologics and Windtree Therapeutics' top-line revenue, earnings per share (EPS) and valuation.
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio |
|---|
| ADMA Biologics | $29.35 million | 6.82 | $-48,280,000.00 | ($0.92) | -1.79 |
| Windtree Therapeutics | $200,000.00 | 280.95 | $-27,480,000.00 | ($2.52) | -0.85 |
Windtree Therapeutics has lower revenue, but higher earnings than ADMA Biologics. ADMA Biologics is trading at a lower price-to-earnings ratio than Windtree Therapeutics, indicating that it is currently the more affordable of the two stocks.
Risk and Volatility
ADMA Biologics has a beta of 1.84, suggesting that its share price is 84% more volatile than the S&P 500. Comparatively, Windtree Therapeutics has a beta of 0.25, suggesting that its share price is 75% less volatile than the S&P 500.
Summary
Windtree Therapeutics beats ADMA Biologics on 8 of the 13 factors compared between the two stocks.
